Publication of Circular.

Verici Dx plc

("Verici" or the "Company")

Publication of Circular

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a Circular, containing a notice of general meeting, has been published today seeking Shareholder approval to issue and allot new Ordinary Shares on a non-pre-emptive basis at a general meeting due to be held at the offices of Shoosmiths LLP at 1 Bow Churchyard, London, EC4M 9DQ at 11:30 a.m. on 27 May 2025 ("General Meeting").

Following the announcement on 7 April 2025, the Company is proposing to carry out a Fundraising (the "Fundraising") to raise funds to enable it, inter alia, to accelerate commercial growth and support the scale up of Tutivia™ revenues. The Fundraising is required to extend the cash runway and enable the Company to achieve its commercial objectives having now secured Medicare Coverage for Tutivia™ as announced on 10 April 2025.

The existing allotment authorities the Company has from its last annual general meeting are anticipated to be insufficient for the proposed Fundraising and accordingly, the Company is proposing to obtain sufficient further authority to issue and allot new Ordinary Shares on a non-pre-emptive basis at the General Meeting.

The size and structure of the Fundraising is yet to be determined by the Board, however it is anticipated to include a placing with institutional and other investors. The Company, in consultation with its advisers, will determine the appropriate size, structure and timing of the Fundraising in due course and a further update will be provided by the Company as and when deemed appropriate.

The Circular and notices of availability of the Circular on the Company's website will be posted to Shareholders today and these documents will also be available later today on the Company's website at:

https://vericidx.com/investors/documents/

Unless otherwise defined, all definitions used in this announcement will have the same meaning as described in the Circular.

Enquiries:

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.